Peppermint Venture Partners

Labfolder is a digital laboratory platform that enhances productivity and efficiency for laboratory teams involved in scientific research and innovation. It features an electronic laboratory notebook (ELN) that organizes and records experimental data, allowing users to document their work seamlessly. Additionally, Labfolder offers a comprehensive automation and monitoring system that integrates various laboratory equipment, laboratory information management systems (LIMS), databases, and specialized software. This connectivity helps eliminate data silos, streamlining data transfer and reducing the risk of errors. The platform also allows for the aggregation of both automatically recorded and manually added data, facilitating easy review, sharing, retrieval, and validation through its collaborative ELN. Labfolder serves diverse fields such as life sciences, chemical synthesis, analytics, and quality control, addressing the common requirements for effective data management across different laboratory tasks.

CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in developing a proprietary cryotherapy system aimed at treating coronary artery disease, which is a leading cause of heart attacks. The company focuses on demonstrating clinical benefits and advancing early-stage commercialization of its innovative catheter system that employs cryoenergy to address issues related to diseased coronary arteries. By proving the safety and efficacy of cryoenergy in the cardiovascular context, CryoTherapeutics aims to provide heart surgeons with an effective tool to prevent heart attacks and enhance patient outcomes.

Implandata Ophthalmic Products GmbH is a medical device company based in Hanover, Germany, founded in 2010. It specializes in developing innovative solutions for the treatment and management of glaucoma, a prevalent eye disease. The company's flagship product, Eyemate, is an implantable micro sensor designed for continuous intraocular pressure measurement. This biocompatible device allows for 24-hour monitoring without compromising the patient's vision or overall well-being. By integrating advanced medical technology with information technology, Implandata aims to enhance the efficiency of glaucoma therapy, benefiting patients, their families, and caregivers. The company's focus on addressing unmet needs in glaucoma care positions it as a significant player in the ophthalmic medical device sector.

Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.

Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.

CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in developing a proprietary cryotherapy system aimed at treating coronary artery disease, which is a leading cause of heart attacks. The company focuses on demonstrating clinical benefits and advancing early-stage commercialization of its innovative catheter system that employs cryoenergy to address issues related to diseased coronary arteries. By proving the safety and efficacy of cryoenergy in the cardiovascular context, CryoTherapeutics aims to provide heart surgeons with an effective tool to prevent heart attacks and enhance patient outcomes.

Emperra E-Health Technologies, founded in 2008 and located in Potsdam, Germany, specializes in developing tele-medical products for diabetes management. The company focuses on creating systems that facilitate the tracking, monitoring, and transmission of diagnostic and therapeutic data for diabetic patients. Emperra's innovative solutions include a Bluetooth-enabled insulin pen and a wireless blood glucose meter, which provide healthcare professionals with essential therapy information. These products enable doctors and nurses to effectively monitor patients' insulin doses, blood sugar levels, and carbohydrate intake, improving overall diabetes care.

CEVEC Pharmaceuticals GmbH specializes in the manufacture of biopharmaceutical molecules featuring human glycosylation patterns. The company develops the CAP-GO platform, which includes optimized expression vectors and a cell line generation process that is free from serum and animal components. This platform enables the efficient production of complex, glycosylated proteins and therapeutic proteins, including monoclonal antibodies. CEVEC also offers the CAP-GT platform for the industrial-scale production of gene therapy vectors, such as Lentiviral, Adenoviral, and AAV types. Additionally, the company provides contract manufacturing services. Founded in 2001 and based in Cologne, Germany, CEVEC has established a strategic collaboration with BioLamina AB to enhance its capabilities in biopharmaceutical production.

Humedics, based in Berlin, focuses on rapid and precise liver function measurement using LiMAx, its innovative breath analysis technology. This easy-to-use bedside test provides doctors with accurate information to support decision making in tailoring the medical treatment to the individual level of each patient and to improve patient outcomes. LiMAx has already been used on thousands of patients and the company is currently expanding its operation globally.

Implandata Ophthalmic Products GmbH is a medical device company based in Hanover, Germany, founded in 2010. It specializes in developing innovative solutions for the treatment and management of glaucoma, a prevalent eye disease. The company's flagship product, Eyemate, is an implantable micro sensor designed for continuous intraocular pressure measurement. This biocompatible device allows for 24-hour monitoring without compromising the patient's vision or overall well-being. By integrating advanced medical technology with information technology, Implandata aims to enhance the efficiency of glaucoma therapy, benefiting patients, their families, and caregivers. The company's focus on addressing unmet needs in glaucoma care positions it as a significant player in the ophthalmic medical device sector.

CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in developing a proprietary cryotherapy system aimed at treating coronary artery disease, which is a leading cause of heart attacks. The company focuses on demonstrating clinical benefits and advancing early-stage commercialization of its innovative catheter system that employs cryoenergy to address issues related to diseased coronary arteries. By proving the safety and efficacy of cryoenergy in the cardiovascular context, CryoTherapeutics aims to provide heart surgeons with an effective tool to prevent heart attacks and enhance patient outcomes.

CAP-CMV GmbH develops vaccines for protection against human Cytomegalovirus (HCMV) infection.

CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in developing a proprietary cryotherapy system aimed at treating coronary artery disease, which is a leading cause of heart attacks. The company focuses on demonstrating clinical benefits and advancing early-stage commercialization of its innovative catheter system that employs cryoenergy to address issues related to diseased coronary arteries. By proving the safety and efficacy of cryoenergy in the cardiovascular context, CryoTherapeutics aims to provide heart surgeons with an effective tool to prevent heart attacks and enhance patient outcomes.

Implandata Ophthalmic Products GmbH is a medical device company based in Hanover, Germany, founded in 2010. It specializes in developing innovative solutions for the treatment and management of glaucoma, a prevalent eye disease. The company's flagship product, Eyemate, is an implantable micro sensor designed for continuous intraocular pressure measurement. This biocompatible device allows for 24-hour monitoring without compromising the patient's vision or overall well-being. By integrating advanced medical technology with information technology, Implandata aims to enhance the efficiency of glaucoma therapy, benefiting patients, their families, and caregivers. The company's focus on addressing unmet needs in glaucoma care positions it as a significant player in the ophthalmic medical device sector.

As of May 13, 2005, weblicon technologies AG was acquired by Synchronica Software GmbH. Weblicon technologies AG is based in Berlin, Germany and develops and markets web-based applications such as online organizer, featuring online calendaring, contact management and e-mail. The company’s product can be integrated into existing networks of servers, applications and databases and is platform-independent and customizable. Major clients are telecommunication companies, portals as well as service providers.